Half-year report · Q2

Period2024-04-01 → 2024-09-30
Filed2024-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥124.8bn2024-04-01 → 2024-09-30Cons.Net sales
Revenue¥180.1bn2023-04-01 → 2024-03-31Cons.Net sales (5-year summary)
Revenue¥88.5bn2023-04-01 → 2023-09-30Cons.Net sales
Operating income¥6.1bn2024-04-01 → 2024-09-30Cons.Operating income
Operating income¥3.6bn2023-04-01 → 2023-09-30Cons.Operating income
Ordinary income¥6.2bn2024-04-01 → 2024-09-30Cons.Ordinary income
Ordinary income¥9.3bn2023-04-01 → 2024-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥3.7bn2023-04-01 → 2023-09-30Cons.Ordinary income
Profit before tax¥5.0bn2024-04-01 → 2024-09-30Cons.Income before income taxes
Profit before tax¥3.6bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Net income (owners)¥1.2bn2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.9bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥1.9bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income¥2.3bn2024-04-01 → 2024-09-30Cons.Profit loss
Net income¥1.9bn2023-04-01 → 2023-09-30Cons.Profit loss
Total assets¥137.3bnat 2024-09-30Cons.Assets
Total assets¥117.8bnat 2024-03-31Cons.Assets
Total assets¥107.4bnat 2023-09-30Cons.Total assets (5-year summary)
Total liabilities¥79.3bnat 2024-09-30Cons.Liabilities
Total liabilities¥64.9bnat 2024-03-31Cons.Liabilities
Net assets / equity¥58.0bnat 2024-09-30Cons.Net assets
Net assets / equity¥52.8bnat 2024-03-31Cons.Net assets
Net assets / equity¥50.3bnat 2023-09-30Cons.Net assets (5-year summary)
Cash and deposits¥21.8bnat 2024-09-30Cons.Cash and deposits
Cash and deposits¥27.3bnat 2024-03-31Cons.Cash and deposits
Cash & equivalents¥21.5bnat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥26.9bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥17.3bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥18.6bnat 2023-03-31dCons.Cash and cash equivalents
Operating cash flow¥477m2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥13.5bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥6.4bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Investing cash flow¥265m2024-04-01 → 2024-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥13.2bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥9.9bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥6.2bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
Financing cash flow¥8.0bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥2.2bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥32.432024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥131.112023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥50.82023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio39.3%at 2024-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio44.8%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio46.8%at 2023-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 36
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30−¥686m
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-09-30−¥686m
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30−¥1.8bn
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentrevenue2024-04-01 → 2024-09-30¥84.1bn
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentrevenue external2024-04-01 → 2024-09-30¥84.1bn
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥64m
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentsegment profit2024-04-01 → 2024-09-30¥4.2bn
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentrevenue2024-04-01 → 2024-09-30¥7.4bn
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentrevenue external2024-04-01 → 2024-09-30¥6.8bn
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥622m
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentsegment profit2024-04-01 → 2024-09-30¥928m
jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥33.9bn
jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥33.9bn
jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥2.7bn
—segment totalrevenue2024-04-01 → 2024-09-30¥125.5bn
—segment totalrevenue external2024-04-01 → 2024-09-30¥124.8bn
—segment totalrevenue intersegment2024-04-01 → 2024-09-30¥686m
—segment totalsegment profit2024-04-01 → 2024-09-30¥7.9bn
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥237m
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥237m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥1.8bn
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentrevenue2023-04-01 → 2023-09-30¥81.0bn
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentrevenue external2023-04-01 → 2023-09-30¥81.0bn
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥63m
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentsegment profit2023-04-01 → 2023-09-30¥4.7bn
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentrevenue2023-04-01 → 2023-09-30¥6.8bn
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentrevenue external2023-04-01 → 2023-09-30¥6.7bn
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥173m
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentsegment profit2023-04-01 → 2023-09-30¥801m
jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥897m
jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥897m
jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segmentsegment profit2023-04-01 → 2023-09-30−¥142m
—segment totalrevenue2023-04-01 → 2023-09-30¥88.8bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥88.5bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥237m
—segment totalsegment profit2023-04-01 → 2023-09-30¥5.4bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 543
ItemContextValueUnit
Net salesPrior1YTDDuration_ReconcilingItemsMember-237000000JPY
Net salesPrior1YTDDuration88540000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q2r_E03476-000HealthInsurancePharmacyReportableSegmentsMember4714000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q2r_E03476-000MedicalRelatedReportableSegmentMember801000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q2r_E03476-000PharmaceuticalBusinessReportableSegmentMember-142000000JPY
Operating incomePrior1YTDDuration_ReportableSegmentsMember5372000000JPY
Operating incomePrior1YTDDuration_ReconcilingItemsMember-1812000000JPY
Operating incomePrior1YTDDuration3559000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E03476-000HealthInsurancePharmacyReportableSegmentsMember84080000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E03476-000MedicalRelatedReportableSegmentMember6755000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E03476-000PharmaceuticalBusinessReportableSegmentMember33936000000JPY
Revenues from external customersCurrentYTDDuration_ReportableSegmentsMember124771000000JPY
Revenues from external customersCurrentYTDDuration_ReconcilingItemsMember-JPY
Revenues from external customersCurrentYTDDuration124771000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q2r_E03476-000HealthInsurancePharmacyReportableSegmentsMember64000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q2r_E03476-000MedicalRelatedReportableSegmentMember622000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q2r_E03476-000PharmaceuticalBusinessReportableSegmentMember-JPY
Transactions with other segmentsCurrentYTDDuration_ReportableSegmentsMember686000000JPY
Transactions with other segmentsCurrentYTDDuration_ReconcilingItemsMember-686000000JPY
Transactions with other segmentsCurrentYTDDuration-JPY
Net salesCurrentYTDDuration_jpcrp040300-q2r_E03476-000HealthInsurancePharmacyReportableSegmentsMember84144000000JPY
Net salesCurrentYTDDuration_jpcrp040300-q2r_E03476-000MedicalRelatedReportableSegmentMember7377000000JPY
Net salesCurrentYTDDuration_jpcrp040300-q2r_E03476-000PharmaceuticalBusinessReportableSegmentMember33936000000JPY
Net salesCurrentYTDDuration_ReportableSegmentsMember125458000000JPY
Net salesCurrentYTDDuration_ReconcilingItemsMember-686000000JPY
Net salesCurrentYTDDuration124771000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q2r_E03476-000HealthInsurancePharmacyReportableSegmentsMember4232000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q2r_E03476-000MedicalRelatedReportableSegmentMember928000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q2r_E03476-000PharmaceuticalBusinessReportableSegmentMember2742000000JPY
Operating incomeCurrentYTDDuration_ReportableSegmentsMember7904000000JPY
Operating incomeCurrentYTDDuration_ReconcilingItemsMember-1807000000JPY
Operating incomeCurrentYTDDuration6096000000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の5第1項の表の第1号
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2024-11-14
Quarterly accounting period cover pageFilingDateInstant
Original text (Japanese)第33期中 (自 2024年4月1日 至 2024年9月30日)
Company name cover pageFilingDateInstant
Original text (Japanese)クオールホールディングス株式会社
Company name in english cover pageFilingDateInstantQol Holdings Co.,Ltd.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長  中村 敬
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)東京都港区虎ノ門四丁目3番1号 城山トラストタワー37階
Telephone number address of registered headquarter cover pageFilingDateInstant03-6430-9060
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)代表取締役常務 福滿 清伸
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京都港区虎ノ門四丁目3番1号 城山トラストタワー37階
Telephone number nearest place of contact cover pageFilingDateInstant03-6430-9060
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)代表取締役常務 福滿 清伸
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE03476
Fund codeFilingDateInstant-
Security codeFilingDateInstant30340

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-03-31pass rounding
balance sheet identityconsolidated 2024-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass